|
The Need for Guidelines and the Use of Economic
Evidence in Decision-Making in Thailand:
Lessons Learnt from the Development of
the National List of Essential Drugs
Suwit Wibulpolprasert MD* On behalf of Subcommittee for Development of the National List of Essential Drugs** |
S1 |
|
|
Making Sensible Rationing: The Use of Economic Evidence
and the Need for Methodological Standards
Viroj Tangcharoensathien MD, PhD*, Pirom Kamolratanakul MD, MSc** |
S4 |
|
|
Making Health Technology Assessment Information
Available for Decision Making: The Development
of a Thai Database
Nattiya Kapol PhD*, Pagamas Maitreemit PhD*, Rapeepun Chalongsuk MSc (Pharm)*, Yaowalak Amrumpai PhD*, Namfon Sribundit MBA*, Montarat Thavorncharoensap PhD**,***, Usa Chaikledkaew MA, PhD **,***, Yot Teerawattananon MD, PhD*** |
S8 |
|
|
Thai Health Technology Assessment Guideline Development
Yot Teerawattananon MD, PhD*, Usa Chaikledkaew MA, PhD*,** |
S11 |
|
|
Defining the Scope of Economic Evaluation Study and
Selection of Comparators
Nathorn Chaiyakunapruk PharmD, PhD*,**,*** |
S16 |
|
|
Defining Types of Economic Evaluation
Surachat Ngorsuraches PhD* |
S21 |
|
|
Measurement of Costs
Arthorn Riewpaiboon B Pharm, MSc, PhD* |
S28 |
|
|
Measurement of Clinical Effects
Yot Teerawattananon MD, PhD*, Montarat Thavorncharoensap PhD*,**, Adun Mohara MSc* |
S38 |
|
|
Measurement of Clinical-Effect: Utility
Phantipa Sakthong PhD* |
S43 |
|
|
Handling Time in Economic Evaluation Studies
Unchalee Permsuwan PhD*, Kansinee Guntawongwan MA**, Piyaluk Buddhawongsa PhD** |
S53 |
|
|
Handling Uncertainty of the Economic Evaluation
Result: Sensitivity Analysis
Supon Limwattananon MPHM, PhD* |
S59 |
|
|
Presentation of Economic Evaluation Results
Usa Chaikledkaew MA, PhD*,**, Yot Teerawattananon MD, PhD** |
S66 |
|
|
Health System and Equity Perspectives in
Health Technology Assessment
Piya Hanvoravongchai MD, MSc* |
S74 |
|
|
Policy Making and Roles of Health Technology Assessment
* International Health Policy Program, Bureau of Policy and Strategy, Ministry of Public Health, Nonthaburi |
S88 |
|
|
A Determination of Topics for Health Technology
Assessment in Thailand: Making Decision
Makers Involved
Chanida Lertpitakpong MA*, Usa Chaikledkaew MA, PhD*,**, Montarat Thavorncharoensap PhD*,**, Sripen Tantivess PhD*, Naiyana Praditsitthikorn MSc*, Sitaporn Youngkong MSc*, Jomkwan Yothasamut MA*, Kanchanart Udomsuk MA*, Kongkoch Sinthitichai*, Yot Teerawattananon MD, PhD* |
S100 |
|
|
Costs of Injuries Due to Interpersonal and Self-Directed
Violence in Thailand, 2005
Kanitta Bundhamcharoen PhD*, Patarapan Odton MSc*, Suwanna Mugem MSc*, Sirinya Phulkerd MSc*, Kanjana Dhisayathikom MA*, David W Brown**, Viroj Tangcharoensathien MD, PhD** |
S110 |
|
|
Cost-Utility Analysis of Recombinant Human
Erythropoietin in Anemic Cancer Patients
Induced by Chemotherapy in Thailand
Jirapan Roungrong Pharm D*,**,***, Yot Teerawattananon MD, PhD*, Usa Chaikledkaew MA, PhD*,** |
S119 |
|
|
The Cost-Effectiveness Analysis of Initiating HIV/AIDS
Treatment with Efavirenz-Based Regimens Compared
with Nevirapine-Based Regimens in Thailand
Usawadee Maleewong*,**, Vithaya Kulsomboon PhD**, Yot Teerawattananon MD, PhD*** |
S126 |
© MEDICAL ASSOCIATION OF THAILAND. All Rights Reserved. The content of this site is intended for health professionals.
